Atypical and anaplastic meningiomas treated with bevacizumab

@article{Norden2012AtypicalAA,
  title={Atypical and anaplastic meningiomas treated with bevacizumab},
  author={Andrew D. Norden and Fabio M. Iwamoto and Jeremy D Rudnick and Andrew David Norden and Eudocia Quant Lee and Jan Drappatz and Diego Morais Corr{\^e}a and Thomas J Kaley},
  journal={Journal of Neuro-Oncology},
  year={2012},
  volume={109},
  pages={187-193}
}
Atypical and anaplastic (WHO Grades II and III) meningiomas are aggressive tumors, and patients often progress despite surgery and radiation. There is no known effective chemotherapeutic option for these patients. Meningiomas have a high expression of vascular endothelial growth factor receptor (VEGFR). We sought to retrospectively study the activity of bevacizumab, which is an anti-angiogenic agent targeting the VEGF pathway in these tumors. This is a retrospective review of WHO Grade II and… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 56 CITATIONS, ESTIMATED 51% COVERAGE

Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review

  • Surgical neurology international
  • 2018
VIEW 6 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Systemic therapy for recurrent meningioma.

  • Expert review of neurotherapeutics
  • 2016
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 2 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 10 REFERENCES

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
VIEW 1 EXCERPT

Phase II trial of sunitinib (SU011248) for recurrent meningioma

TJ Kaley, D Schiff, S Karimi
  • Neurooncology 12(Suppl
  • 2010

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
VIEW 1 EXCERPT